Russell Investments Group
CRVS icon

Russell Investments Group’s Corvus Pharmaceuticals CRVS Stock Holding History

Russell Investments Group’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$379K Buy
25,337
+18,542
+273% +$257K ﹤0.01% 2910
2026
Q1 		$99.4K Buy
6,795
+134
+2% +$2.14K ﹤0.01% 3089
2025
Q4 		$51.3K Hold
6,661
– – ﹤0.01% 3290
2025
Q3 		$49.1K Buy
+6,661
New +$34.1K ﹤0.01% 3297
2021
Q1 		– Sell
-34,117
Closed -$120K – 3116
2020
Q4 		$120K Sell
34,117
-2,897
-8% -$11.7K ﹤0.01% 2844
2020
Q3 		$148K Sell
37,014
-2,157
-6% -$8.62K ﹤0.01% 2889
2020
Q2 		$106K Buy
39,171
+8,951
+30% +$26.4K ﹤0.01% 2872
2020
Q1 		$63K Buy
+30,220
New +$123K ﹤0.01% 2838
2018
Q1 		– Sell
-1,500
Closed -$16K – 2921
2017
Q4 		$16K Sell
1,500
-4,904
-77% -$62.8K ﹤0.01% 2928
2017
Q3 		$102K Sell
6,404
-2,882
-31% -$39.9K ﹤0.01% 2771
2017
Q2 		$112K Buy
9,286
+2,105
+29% +$22.5K ﹤0.01% 2788
2017
Q1 		$149K Sell
7,181
-19,229
-73% -$301K ﹤0.01% 2763
2016
Q4 		$402K Buy
+26,410
New +$402K ﹤0.01% 2540

Other funds holding CRVS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.97B AUM 30.33% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Russell Investments Group's CRVS Position: Q2 2026 in Review

Russell Investments Group increased its Corvus Pharmaceuticals (CRVS) stake by 273% in Q2 2026, buying an estimated $257K and bringing the position to 25,337 shares worth $379K. The position accounts for ﹤0.01% of the portfolio, ranked #2910.

Russell Investments Group first reported a position in CRVS in Q4 2016 and has held it in 13 quarters since. The position peaked at $402K in Q4 2016. 59 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Russell Investments Group held 25,337 shares of Corvus Pharmaceuticals worth $379K as of Q2 2026.
  • Russell Investments Group bought 18,542 Corvus Pharmaceuticals shares in Q2 2026, an estimated $257K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2910 holding.
  • Russell Investments Group first reported a position in Corvus Pharmaceuticals in Q4 2016 and has held it in 13 quarters since.
  • Russell Investments Group's Corvus Pharmaceuticals position peaked at $402K in Q4 2016.
  • 59 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.